peopleimages-2-

peopleimages / iStockphoto.com

22 August 2017Asia-Pacific

Samsung makes move into novel drugs market

Samsung’s biopharmaceutical arm Samsung Bioepis has agreed a deal with Takeda to tackle “unmet disease areas”, marking the South Korean company’s move into the novel drugs market.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?